Phase I trial of epirubicin and taxotere [docetaxel] in patients with metastatic androgen independent prostate cancer
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Docetaxel (Primary) ; Epirubicin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 12 Apr 2018 Last checked against ClinicalTrials.gov.
- 06 Apr 2018 Status changed from completed to discontinued.
- 04 Dec 2008 Status changed from suspended to completed, according to clinicaltrials.gov.